In­dus­try vet Ken Moch jumps to the helm of a small biotech with big dreams for treat­ing Alzheimer’s

Long­time biotech vet Ken Moch will be spend­ing a good part of his work­ing hours in Pitts­burgh from now on. The for­mer Chimerix CEO has land­ed the helm of Cog­ni­tion Ther­a­peu­tics, a small biotech which is pur­su­ing ear­ly-stage work on a new Alzheimer’s drug.

“I’ve known the com­pa­ny for awhile,” Moch tells me about his move, two years af­ter he left Chimerix in the wake of a vi­ral con­tro­ver­sy over ac­cess to that com­pa­ny’s lead an­ti-vi­ral. Cog­ni­tion (AKA CogRx), he says, “has very ex­cit­ing tech­nol­o­gy.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER